Th17细胞与肿瘤免疫的研究进展

何宋兵; 朱新国

doi:10.3969/j.issn.1000-8179.2012.09.012

Th17细胞与肿瘤免疫的研究进展

doi: 10.3969/j.issn.1000-8179.2012.09.012

何宋兵,
朱新国^,

苏州大学附属第一医院普外科（江苏省苏州市215006）

基金项目:

江苏省医学科研计划项目 H201013

江苏省研究生科研创新计划项目 CX10B_054Z

江苏省苏州市科教兴卫青年科技项目 SWKQ1004

详细信息

通讯作者:
朱新国 hesongbing2@yahoo.com.cn

计量
- 文章访问数: 33
- HTML全文浏览量: 1
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2011-12-20
- 修回日期: 2012-03-07

Advances in the Research on T helper 17 Cells and Tumor Immunity

Songbing HE,
Xinguo ZHU^,

Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China

Funds:

Medical Science and Technology Development Foundation, Jiangsu Province Department of Health, China H201013

Program for Postgraduate Research Innovation in University of Jiangsu Province, China CX10B_054Z

Project of Youth Foundation in Science and Education of Department of Public Health of Suzhou, China SWKQ1004

More Information

Corresponding author: Xinguo ZHU, E-mail: hesongbing2@yahoo.com.cn

摘要

摘要: Th17细胞是一类与Th1、Th2及Treg细胞不同的新型效应CD4⁺T细胞，研究已证实Th17细胞在感染、炎症、自身免疫性疾病及移植物抗宿主病中具有关键的致病作用。近来研究发现Th17细胞同样存在于肿瘤微环境中，并与炎症相关性肿瘤的发生有一定关系，但目前对Thl7细胞在肿瘤微环境中的分化发育条件、免疫调控机制及具体功能效应尚不完全清楚。本文将对Th17细胞及其相关细胞因子与肿瘤免疫相关性的研究进展作一简要综述。
- 肿瘤 /
- IL-17 /
- Th17细胞 /
- 肿瘤微环境 /
- 炎症
Abstract: Th17 cells have recently been classified as a new effector T-cell subset which is distinct from Th1, Th2 and Treg subsets. Since Th17 cells were found, studies confirmed that these cells had critical roles in infection, inflammation, autoimmune diseases, and graft versus host disease. Moreover, Thl7 cells have been recently found in some human cancers, but the differentiation and development condition, regulation mechanisms and functional effects of Th17 cells remains controversial. This review summarizes recent findings regarding the correlation of Thl7 cells and malignant tumor related cytokines with tumor immunity.
- Neoplasm /
- IL-17 /
- Th17 cells /
- Tumor microenvironment /
- Inflammation

HTML全文

参考文献(23)

[1]	Sautes-Fridman C, Cherfils-Vicini J, Damotte D, et al. Tumor microenvironment is multifaceted[J]. Cancer Metastasis Rev, 2011, 30 (1): 13-25. doi: 10.1007/s10555-011-9279-y
[2]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell[J]. 2011, 144(5): 646-674.
[3]	Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells[J]. Annu Rev Immunol, 2009, 27: 485-517. doi: 10.1146/annurev.immunol.021908.132710
[4]	Tesmer LA, Lundy SK, Sarkar S, et al. Th17 cells in human disease [J]. Immunol Rev, 2008, 223: 87-113. doi: 10.1111/j.1600-065X.2008.00628.x
[5]	Ye ZJ, Zhou Q, Gu YY, et al. Generation and differentiation of IL-17-producing CD4 + T cells in malignant pleural effusion[J]. J Immunol, 2010, 185(10): 6348-6354. doi: 10.4049/jimmunol.1001728
[6]	Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling[J]. Nature, 2010, 467(7318): 967-971. doi: 10.1038/nature09447
[7]	Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR gammat function[J]. Nature, 2008, 453(7192): 236-240. doi: 10.1038/nature06878
[8]	Manel N, Unutmaz D, Littman DR. The differentiation of human Th17 cells requires transforming growth factor-beta and induction of the nuclear recep tor ROR gamma-t[J]. Nature Immunol, 2008, 9(6): 641-649. doi: 10.1038/ni.1610
[9]	Leppkes M, Becker C, Ivanov Ⅱ, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F[J]. Gastroenterology, 2009, 136 (1): 257-267. doi: 10.1053/j.gastro.2008.10.018
[10]	Chen Q, Yang W, Gupta S, et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor[J]. Immunity, 2008, 29(6): 899-911. doi: 10.1016/j.immuni.2008.10.011
[11]	Atarashi K, Nishinura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation[J]. Nature, 2008, 455(7214): 808-812. doi: 10.1038/nature07240
[12]	Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments[J]. Blood, 2009, 114: 1141-1149.
[13]	Zhang B, Rong G, Wei H, et al. The prevalence of Th17 cells in patients with gastric cancer[J]. Biochem Biophys Res Commun, 2008, 374(3): 533-537. doi: 10.1016/j.bbrc.2008.07.060
[14]	Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients [J]. J Hepatol, 2009, 50(5): 980-989. doi: 10.1016/j.jhep.2008.12.033
[15]	Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment[J]. J Immunol, 2007, 178(11): 6730-6733. doi: 10.4049/jimmunol.178.11.6730
[16]	Hu J, Yuan X, Belladonna ML, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells[J]. Cancer Res, 2006, 66(17): 8887-8896. doi: 10.1158/0008-5472.CAN-05-3448
[17]	Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth[J]. Blood, 2003, 101(7): 2620-2627. doi: 10.1182/blood-2002-05-1461
[18]	Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway[J]. J Exp Med, 2009, 206(7): 1457-1464. doi: 10.1084/jem.20090207
[19]	Kuang DM, Peng C, Zhao Q, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells[J]. Hepatology, 2010, 51(1): 154-164. doi: 10.1002/hep.23291
[20]	Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma[J]. Blood, 2008, 112 (2): 362-373. doi: 10.1182/blood-2007-11-120998
[21]	Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells[J]. Curr Opin Immunol, 2007, 19(3): 281-286. doi: 10.1016/j.coi.2007.04.005
[22]	Gnerlich JL, Mitchem JB, Weir JS, et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer[J]. J Immunol, 2010, 185(7): 4063-4071. doi: 10.4049/jimmunol.0902609
[23]	Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis[J]. Blood, 2009, 114(2): 357-359. doi: 10.1182/blood-2008-09-177360